In the same study, increased USP9X in multiple myeloma patients correlates with poor survival and the authors conclude that USP9X stabilizes MCL1, one member of pro-survival BCL2 family, and promotes tumor cell survival [15]. Here, MCL1 is linked to plasma cell myeloma.